Relapse-free cure from multidrug-resistant tuberculosis in Germany
Multidrug-resistant (MDR) tuberculosis (TB), defined by bacillary resistance against rifampicin and isoniazid, has been identified as a global threat to mankind [1]. According to the latest report by the European Centres for Disease Prevention and Control, and World Health Organization (WHO) regional office for Europe, only approximately 50% of MDR-TB patients in Europe reach favourable treatment outcomes [2]. Successful treatment outcomes are achieved for less than 25% of patients with extensively drug-resistant (XDR)-TB (MDR plus resistance against a least one fluoroquinolone and one second-line injectable drug) in the European Union/European Economic Area Countries [2].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Heyckendorf, J., van Leth, F., Kalsdorf, B., Olaru, I. D., Günther, G., Salzer, H. J. F., Terhalle, E., Rolling, T., Glattki, G., Müller, M., Schuhmann, M., Avsar, K., Lange, C. Tags: Respiratory infections and tuberculosis Original Articles: Research letters Source Type: research